Pembrolizumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Explore 59 assets in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Seda S. Tolu
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07283822CT.gov Amping up With PemJAK | — | Recruiting | — | — | — |
NCT05956041CT.gov Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | — | Recruiting | — | — | — |
NCT03240211CT.gov Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | — | Active Not Recruiting | — | — | — |
NCT03385226CT.gov A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) | — | Active Not Recruiting | — | — | — |
NCT03617224CT.gov Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome | — | Withdrawn | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT03063632CT.gov Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | — | Completed | — | — | — |
NCT03278782CT.gov Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | — | Active Not Recruiting | — | — | — |
NCT02243579CT.gov Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Seda S. Tolu | P2 | BB · 64 |
| (+)-Vincristine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Cyclophosphamide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Bexarotene | Case Comprehensive Cancer Center | P4 | BBB |
| Dexasone | National Cancer Institute (NCI) | P2 | BBB |
| Nivestim | City of Hope Medical Center | P4 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BBB |
| Adriamycin | Falo, Louis, MD | P4 | BBB |
| Etoposide | City of Hope Medical Center | P2 | BB |
+42 more in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-primary-cutaneous-t-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →